About: The effects of renin-angiotensin system inhibitors (RASI) in Corona Virus Disease (COVID-19) with Hypertension: A retrospective, single-center trial

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: The effects of renin-angiotensin system inhibitors (RASI) in Corona Virus Disease (COVID-19) with Hypertension: A retrospective, single-center trial Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	The effects of renin-angiotensin system inhibitors (RASI) in Corona Virus Disease (COVID-19) with Hypertension: A retrospective, single-center trial
Creator	Wu, Feng Cheng, Xin Cheng, Jilin Fan, Zhenyu Feng, Wu Cui, Haiming Fan, Min Hm, Cui Jl, Cheng Zy, Fan
Source	Elsevier; Medline; PMC
abstract	Abstract Introduction and objective: A recent outbreak of Coronavirus disease 2019 (COVID-19) occurs in the worldwide. Angiotensin-converting enzyme 2 (ACE2) can mediate coronavirus entry into host cells. Therefore, renin-angiotensin system inhibitors (RASI) were suspected of contributing to the increase of coronavirus infection. We aimed to analyze the effects of RASI in COVID-19 patients with Hypertension. Patients and method: In this retrospective, single-center study, 27 COVID-19 patients with hypertension, who were admitted to the Shanghai Public Health Clinical Center from January 25, 2020 to January 31, 2020, were analyzed for clinical features, laboratory parameters, medications and the length of stay. All the patients were given antiviral and antihypertension treatment, of which 14 patients were treated with RASI and 13 patients without RASI. Results: Comparing the two groups, we did not found statistically significant differences in clinical symptoms and laboratory tests. Furthermore, cough was not aggravated. Conclusions: Through the analysis of this small sample, RASI could be deemed safe and effective to control high blood pressure of COVID-19 patients. Further analysis with a larger sampling size is required to explore the underlying mechanisms.
has issue date	2020-06-11(xsd:dateTime)
bibo:doi	10.1016/j.medcli.2020.06.007
bibo:pmid	32747012
has license	els-covid
sha1sum (hex)	f0d43d8464e1f7bda6d9e0fb51eb9f43625a5324
schema:url	https://doi.org/10.1016/j.medcli.2020.06.007
resource representing a document's title	The effects of renin-angiotensin system inhibitors (RASI) in Corona Virus Disease (COVID-19) with Hypertension: A retrospective, single-center trial
has PubMed Central identifier	PMC7287454
has PubMed identifier	32747012
schema:publication	Med Clin (Barc)
resource representing a document's body	covid:f0d43d8464e1f7bda6d9e0fb51eb9f43625a5324#body_text
is schema:about of	named entity 'mediate' named entity 'RASI' named entity 'renin-angiotensin system' named entity 'LABORATORY' named entity 'ENTRY INTO HOST' named entity 'PATIENTS' named entity 'WORLDWIDE' named entity 'TREATMENT' named entity 'PARAMETERS' named entity 'CLINICAL FEATURES' named entity 'MEDICATIONS' named entity 'ACE2' named entity 'effects' named entity 'length' named entity 'laboratory' named entity 'infection' named entity 'Corona' named entity 'Hypertension' named entity 'retrospective' named entity 'antiviral' named entity 'Angiotensin-converting enzyme 2' named entity 'Coronavirus disease 2019' named entity 'coronavirus' named entity 'ACE2' named entity 'COVID' named entity 'lymphocyte' named entity 'hypertension' named entity 'white blood cell count' named entity 'phlegm' named entity 'SARS-CoV-2' named entity 'Coronavirus disease 2019' named entity 'regulatory pathway' named entity 'heart failure' named entity 'coronavirus infection' named entity 'prognosis' named entity 'epidemiological' named entity 'ACE2' named entity 'Renin' named entity 'cough' named entity 'COVID' named entity 'informed consent' named entity 'analyzing the data' named entity 'regulatory pathway' named entity 'CRP' named entity 'CEST' named entity 'SARS-CoV' named entity 'hypertension' named entity 'hypertension' named entity 'spike protein' named entity 'antihypertensive' named entity 'Shanghai' named entity 'ACEI' named entity '80 years' named entity 'ACE2' named entity 'Cough' named entity 'bradykinin' named entity 'triglyceride' named entity 'common cold' named entity 'coronavirus infection' named entity 'public health' named entity 'pneumonia' named entity 'research team' named entity 'COVID' named entity 'COVID-19 infection' named entity 'coronavirus' named entity 'hypertension' named entity 'antihypertensive drugs' named entity 'traditional Chinese medicine' named entity 'ACEI' named entity 'hypertension' named entity 'Cough' named entity 'virus'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software